Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.500 GeneticVariation group BEFREE Acetate is required for epidermal growth factor receptor vIII mutation in lethal brain tumors. 30593413 2019
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.500 Biomarker group BEFREE In this study, we developed a cyclic peptide iRGD (CCRGDKGPDC)-conjugated solid lipid nanoparticle (SLN) to deliver small interfering RNAs (siRNAs) against both epidermal growth factor receptor (EGFR) and PD-L1 for combined targeted and immunotherapy against glioblastoma, the most aggressive type of brain tumors. 30916923 2019
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.500 Biomarker group BEFREE The developed multiscale model revealed angiogenesis-induced drug resistance mechanisms of brain tumors to EGFRI treatment and predicted a synergistic drug combination targeting both EGFR and VEGFR pathways with optimal combination timing. 31074391 2019
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.500 AlteredExpression group BEFREE Overexpression of EGFR is detected in some pediatric brain tumors including diffuse intrinsic pontine gliomas (DIPG)s. 30417211 2019
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.500 GeneticVariation group BEFREE Changes in expression of histone deacetylases (HDACs), which epigenetically regulate chromatin structure, and mutations and amplifications of the EGFR gene, which codes for the epidermal growth factor receptor (EGFR), have been reported in glioblastoma (GBM), the most common and malignant type of brain tumor. 30887411 2019
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.500 Biomarker group BEFREE Level 1: The use of afatinib is not recommended in patients with brain metastasis due to breast cancer.There is insufficient evidence to make recommendations regarding: the use of epidermal growth factor receptor inhibitors erlotinib and gefitinib in patients with brain metastasis due to nonsmall cell lung cancerthe use of BRAF inhibitors dabrafenib and vemurafenib in the treatment of patients with brain metastases due to metastatic melanomathe use of HER2 agents trastuzumab and lapatinib to treat patients with brain metastases due to metastatic breast cancerthe use of vascular endothelial growth factor agents bevacizumab, sunitinib, and sorafenib in the treatment of patients with solid tumor brain metastases.The full guideline can be found at: https://www.cns.org/guidelines/guidelines-treatment-adults-metastatic-brain-tumors/chapter_9. 30629215 2019
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.500 AlteredExpression group BEFREE OBJECTIVE High-grade glial brain tumors are often characterized by an elevated expression of the tumorigenic epidermal growth factor receptor variant III ( EGFRvIII). 28574310 2018
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.500 GeneticVariation group BEFREE Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma. 30187121 2018
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.500 GeneticVariation group BEFREE This material architecture effectively delivers the EGFR kinase inhibitor Erlotinib (ERL) and Doxorubicin (DOX, DNA intercalator) in an ERL→DOX sequential manner to synergistically kill glioblastoma, the most aggressive form of brain cancer. 30240496 2018
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.500 GeneticVariation group BEFREE EGFR is also amplified or mutated in a variety of cancers including in nearly 60% of cases of the highly lethal brain cancer glioblastoma (GBM). 28892308 2018
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.500 GeneticVariation group BEFREE <b>Purpose:</b> The epidermal growth factor receptor variant III (<i>EGFRvIII</i>) mutation has been considered a driver mutation and therapeutic target in glioblastoma, the most common and aggressive brain cancer. 28428190 2017
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.500 AlteredExpression group BEFREE Additionally, gefitinib inhibited the phosphorylation of EGFR better than the other drugs, whereas pEGFR expression levels in erlotinib groups were lower than levels in the icotinib group (<i>p</i><sub>gefitinib vs. erlotinib</sub>=0.995; <i>p</i><sub>gefitinib vs. icotinib</sub>=0.028; <i>p</i><sub>erlotinib vs. icotinib</sub>=0.042).Altogether, our findings suggest that gefitinib and erlotinib can inhibit the growth of PC-9-luc brain tumors. 29228726 2017
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.500 GeneticVariation group BEFREE EGFRvIII, a variant of epidermal growth factor receptor (EGFR), is found in 20% of glioblastoma cases, which is the brain tumor with the highest malignancy. 28569328 2017
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.500 Biomarker group BEFREE Adoptive cell therapy (ACT) using T cells engineered with chimeric antigen receptor (CAR) targeting an ideal molecular marker in GBM, e.g. epidermal growth factor receptor type III (EGFRvIII) has demonstrated a satisfactory efficacy in treating malignant brain tumors. 28302023 2017
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.500 GeneticVariation group BEFREE EVs produced by specific brain tumor cell types may contain the corresponding oncogenic drivers, such as epidermal growth factor receptor variant III (EGFRvIII) in glioblastoma (and hence are often referred to as 'oncosomes'). 26993504 2016
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.500 GeneticVariation group CLINVAR Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. 26619011 2016
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.500 AlteredExpression group BEFREE In newly developed double tumor xenogeneic mouse models of brain metastasis this noninvasive method allowed differential diagnosis of HER2- and EGFR-expressing brain tumors. 25906400 2015
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.500 Biomarker group BEFREE The naturally secreted and O-GlcNAcylated MIF binds to EGFR, thereby inhibiting the binding of EGF to EGFR and EGF-induced EGFR activation, phosphorylation of ERK and c-Jun, cell invasion, proliferation and brain tumour formation. 26280537 2015
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.500 AlteredExpression group BEFREE In glioblastoma (GBM), a lethal form of brain cancer, the heterogeneous expression of the epidermal growth factor receptor (EGFR) poses a substantial challenge for the effective use of EGFR-targeted therapies. 25855404 2015
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.500 Biomarker group BEFREE Phosphorylation of Glutathione S-Transferase P1 (GSTP1) by Epidermal Growth Factor Receptor (EGFR) Promotes Formation of the GSTP1-c-Jun N-terminal kinase (JNK) Complex and Suppresses JNK Downstream Signaling and Apoptosis in Brain Tumor Cells. 26429914 2015
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.500 AlteredExpression group BEFREE Optical imaging of targeted β-galactosidase in brain tumors to detect EGFR levels. 25775241 2015
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.500 Biomarker group BEFREE The mechanisms that drive therapeutic resistance to EGFR inhibitors in brain tumours are not well defined, and drug resistance contributes to the deadly and aggressive nature of the disease. 25103728 2014
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.500 Biomarker group BEFREE Here, human brain tumor-initiating cell (BTIC) lines with different combinations of endogenous EGFR wild-type, EGFRvIII, and PTEN mutations were used to investigate response to the EGFR inhibitor gefitinib, mTORC1 inhibitor rapamycin, and dual mTORC1/2 inhibitor AZD8055 alone and in combination with temozolomide (TMZ) EXPERIMENTAL DESIGN: In vitro growth inhibition and cell death induced by gefitinib, rapamycin, AZD8055, and TMZ or combinations in human BTICs were assessed by alamarBlue, neurosphere, and Western blotting assays. 25316808 2014
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.500 GeneticVariation group BEFREE EGFR mutation-induced alternative splicing of Max contributes to growth of glycolytic tumors in brain cancer. 23707073 2013
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.500 GeneticVariation group BEFREE Patients diagnosed with NSCLC harboring EGFR mutation and measurable metastatic brain tumors were eligible. 22677429 2012